Analyst Ratings For Mirum Pharmaceuticals

In the preceding three months, 10 analysts have released ratings for Mirum Pharmaceuticals MIRM, presenting a wide array of perspectives from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $52.6, a high estimate of $72.00, and a low estimate of $35.00. This current average represents a 1.29% decrease from the previous average price target of $53.29.

Investigating Analyst Ratings: An Elaborate Study

A comprehensive examination of how financial experts perceive Mirum Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Mirum Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Mirum Pharmaceuticals compared to the broader market.
• Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Mirum Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Mirum Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Mirum Pharmaceuticals analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Mirum Pharmaceuticals: A Closer Look

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Financial Insights: Mirum Pharmaceuticals

Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.

Positive Revenue Trend: Examining Mirum Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 149.24% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Mirum Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -51.27%, the company demonstrates strong profitability and effective cost management.

Return on Equity (ROE): Mirum Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of -13.77%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Mirum Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of -5.5%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Mirum Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.24, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

How Are Analyst Ratings Determined?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.